| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Net revenue | ||||||
260,981 | 193,449 | 198,508 | 138,732 | |||
Cost of goods sold | ||||||
75,948 | 68,808 | 61,220 | 48,201 | |||
Gross profit | ||||||
185,033 | 124,641 | 137,288 | 90,531 | |||
Operating expenses: | ||||||
Selling, general and administrative | ||||||
199,693 | 161,961 | 133,717 | 93,029 | |||
Research and development | ||||||
14,799 | 10,742 | 9,065 | 6,277 | |||
Write-off of deferred offering costs | ||||||
0 | 3,494 | - | - | |||
Total operating expenses | ||||||
214,492 | 176,197 | 142,782 | 99,306 | |||
Loss from operations | ||||||
-29,459 | -51,556 | -5,494 | -8,775 | |||
Other expense, net: | ||||||
Interest expense, net | ||||||
8,996 | 10,789 | 8,010 | 5,627 | |||
Interest income | ||||||
- | - | - | 153 | |||
Change in fair value of warrants | ||||||
0 | 469 | 1,037 | 737 | |||
Loss on the extinguishment of debt | ||||||
-1,862 | -2,095 | - | - | |||
Other income, net | ||||||
13 | 162 | -9 | 285 | |||
Total other expense, net | ||||||
-10,845 | -13,191 | -9,056 | -5,926 | |||
Net loss before income taxes | ||||||
-40,304 | -64,747 | -14,550 | -14,701 | |||
Income tax expense | ||||||
150 | 84 | -7,025 | 65 | |||
Net loss | ||||||
-40,454 | -64,831 | -7,525 | -14,766 | |||
Net income attributable to non-controlling interest in affiliates | ||||||
- | - | 863 | 2,221 | |||
Net loss | ||||||
-40,454 | -64,831 | -8,388 | -16,987 | |||
Accretion of redeemable common shares | ||||||
- | - | -423 | - | |||
Non-cash deemed dividend to warrant holders | ||||||
-645 | - | - | - | |||
Net loss attributed to Organogenesis Holdings Inc. common shareholders | ||||||
-41,099 | -64,831 | -8,811 | - | |||
Net loss per share—basic and diluted | ||||||
-0.44 | -0.94 | -0.14 | -0.27 | |||
Weighted-average common shares outstanding—basic and diluted | ||||||
92,840 | 69,318 | 63,876 | 63,196 | |||